SiMPLI next – Advancing in-vitro through innovation and ergonomics
MEDITRANS represents a multidisciplinary Integrated Project dealing with targeted nanomedicines. Platform technologies will be developed with broad applicability to disease treatment, as exemplified by the choice for chronic inflammatory disorders (rheumatoid arthritis, Crohn’s disease, multiple sclerosis), and cancer as target pathologies. Nanomedicines (based on carrier materials like polymeric and lipidic nanoparticles, nanotubes, and fullerenes) will be endowed with superior targeting and (triggerable)
The consortium consists of 29 partners from 9 EU member states (including 1 new member state) and 3 associated states, and includes 12 industrial companies, 12 universities and 5 research institutes. The total budget is €14.8M with €10.7M as EC contribution and €4.1M as industrial support.
The MEDITRANS project has clear potential to forward targeted nanomedicines to the clinic, and will contribute to improved structural collaboration between industry and academia. with a focus on nanotechnology associated with
SiMPLI next – Advancing in-vitro through innovation and ergonomics